

# Ilia Atanelishvili

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11876765/publications.pdf>

Version: 2024-02-01

9  
papers

276  
citations

1478505

6  
h-index

1474206

9  
g-index

9  
all docs

9  
docs citations

9  
times ranked

578  
citing authors

#	ARTICLE	IF	CITATIONS
1	Roles of Proteoglycans and Glycosaminoglycans in Wound Healing and Fibrosis. International Journal of Cell Biology, 2015, 2015, 1-20.	2.5	137
2	Transforming growth factor $\beta$ 1 (TGF $\beta$ 1)-induced CD44V6-NOX4 signaling in pathogenesis of idiopathic pulmonary fibrosis. Journal of Biological Chemistry, 2017, 292, 10490-10519.	3.4	68
3	Utilization of Glycosaminoglycans/Proteoglycans as Carriers for Targeted Therapy Delivery. International Journal of Cell Biology, 2015, 2015, 1-25.	2.5	23
4	Thrombin Increases Lung Fibroblast Survival while Promoting Alveolar Epithelial Cell Apoptosis via the Endoplasmic Reticulum Stress Marker, CCAAT Enhancer Binding Homologous Protein. American Journal of Respiratory Cell and Molecular Biology, 2014, 50, 893-902.	2.9	18
5	Differential DNA Methylation Landscape in Skin Fibroblasts from African Americans with Systemic Sclerosis. Genes, 2021, 12, 129.	2.4	12
6	M10, a caspase cleavage product of the hepatocyte growth factor receptor, interacts with Smad2 and demonstrates antifibrotic properties in <i>vitro</i> and <i>in vivo</i> . Translational Research, 2016, 170, 99-111.	5.0	8
7	Establishment of an indirect ELISA for detection of the novel antifibrotic peptide M10. PLoS ONE, 2017, 12, e0188588.	2.5	6
8	D1398G Variant of MET Is Associated with Impaired Signaling of Hepatocyte Growth Factor in Alveolar Epithelial Cells and Lung Fibroblasts. PLoS ONE, 2016, 11, e0162357.	2.5	2
9	Antifibrotic efficacy of nintedanib in a cellular model of systemic sclerosis-associated interstitial lung disease. Clinical and Experimental Rheumatology, 2019, 37 Suppl 119, 115-124.	0.8	2